Welcome to our dedicated page for NAYA Biosciences SEC filings (Ticker: NAYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing is hard enough—NAYA Biosciences adds another layer of complexity by combining clinical-stage oncology research with a revenue-generating fertility service. Investors hunting for fertility clinic margins, FLEX antibody trial data, or cash runway details can spend hours inside a 300-page 10-K. That’s the problem we solve.
Stock Titan delivers every NAYA Biosciences SEC document—10-K annual report, 10-Q quarterly earnings, 8-K material events, S-1 prospectus, and real-time Form 4 insider trades—alongside AI-powered summaries that translate technical jargon into plain language. Ask the natural questions users type into Google—“Where can I find the NAYA Biosciences quarterly earnings report 10-Q filing?” or “How are NAYA Biosciences executive stock transactions Form 4 reported?”—and land on insights, not PDFs.
Here’s what you’ll uncover:
- Segment clarity: Separate fertility revenue from R&D spend in seconds.
- Clinical milestone tracking: AI flags trial results buried in 8-K material events.
- Insider sentiment: Monitor NAYA Biosciences insider trading Form 4 transactions the moment they hit EDGAR.
- Governance details: Understand the proxy statement executive compensation without legalese.
Whether you’re decoding a NAYA Biosciences annual report 10-K simplified, following NAYA Biosciences earnings report filing analysis, or simply need NAYA Biosciences SEC filings explained simply, our platform keeps you ahead with expert commentary and real-time alerts.
NAYA Biosciences presents condensed results and material transactions for the period ended June 30, 2025. Consolidated revenue is reported at $3,500,839. The filing shows significant losses and non‑cash charges, including impairment charges of $1,397,353 and $14,645,069 and reported net loss amounts shown as $(5,284,858) and $(22,688,444) in the disclosed tables. The company records goodwill of $5,878,986 and finite‑lived intangible assets including tradenames and noncompetition agreements.
Liquidity and financing activity are highlighted: the company reports liquidity figures of $22.7 million and $3.8 million (as presented), an accumulated deficit of approximately $90.2 million, and net cash used in operating activities of approximately $5.3 million for the six months ended June 30, 2025 (versus $1.7 million for the prior period). Financing proceeds included approximately $8.7 million from a public offering, warrant exercises and preferred issuances; the company states it will require additional funding to meet cash needs over the next 12 months. Material business combinations and dispositions (NTI transaction and related note receivable of $4,803,175) and settlement obligations (scheduled payments totaling $5,000,000 under a term sheet) are disclosed.
FAQ
What is the current stock price of NAYA Biosciences (NAYA)?
What is the market cap of NAYA Biosciences (NAYA)?
